Sign In
Buy PRQR
$1.47
+0 (+0%)
At Close: Jun 03, 2026
ProQR Announces Upcoming Investor Conferences in April and May
08:00am, Thursday, 20'th Apr 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
Why Shares of ProQR Therapeutics Dropped on Wednesday
12:30pm, Wednesday, 29'th Mar 2023
ProQR focuses on RNA cell-editing therapies to treat rare diseases. The company lost roughly $117 million in cash in 2022.
ProQR to Present at Upcoming Scientific and Industry Conferences
08:00am, Tuesday, 07'th Mar 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, t
5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts
01:52pm, Tuesday, 27'th Dec 2022
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, N
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
01:32pm, Friday, 23'rd Dec 2022
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
New Years Penny Stocks Trading Advice: 3 Tips
06:00am, Friday, 23'rd Dec 2022
What you need to know about trading penny stocks as the year ends The post New Years Penny Stocks Trading Advice: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock
Why Is ProQR (PRQR) Stock Up 83% Today?
12:51pm, Thursday, 22'nd Dec 2022
ProQR (NASDAQ: PRQR ) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (NYSE: LLY ). This agreement concerns ProQR's Axiomer RNA editing platform.
2 Biotech Stocks Making Headlines
10:42am, Thursday, 22'nd Dec 2022
Two biotech stocks are in the spotlight today, ProQR Therapeutics NV (NASDAQ:PRQR) and Mirati Therapeutics Inc (NASDAQ:MRTX), with the former attracting plenty of options activity.
ProQR's stock jumps on expanded RNA deal with Lilly
09:12am, Thursday, 22'nd Dec 2022
Shares of ProQR Therapeutics NV PRQR, +1.85% soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc. LLY, +2.33% aimed at making
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
06:15am, Thursday, 22'nd Dec 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, to
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tran
ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates
09:47am, Wednesday, 09'th Nov 2022
ProQR (PRQR) delivered earnings and revenue surprises of -47.83% and 7.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Raymond James Bullish On This Penny Stock's Reprioritized Pipeline
06:05pm, Friday, 12'th Aug 2022 Benzinga
Raymond James upgraded ProQR Therapeutics N.V. (NASDAQ: PRQR) to Outperform based on a high conviction that "RNA editing" emerges as an impactful field of therapeutics in coming years.
Related:
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
02:14pm, Friday, 12'th Aug 2022 Benzinga
Upgrades
Mizuho upgraded the previous rating for Safehold Inc (NYSE:SAFE) from Neutral to Buy. For the second quarter, Safehold had an EPS of $0.37, compared to year-ago quarter EPS of $0.28. At the
ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates
02:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
